Agenus Highlights Cancer Drug Development and Improved Balance Sheet at Annual Meeting

At its annual meeting, Agenus focused on the progress of its cancer drug candidates, particularly BOT/BAL, and reported improvements in its balance sheet, signaling positive developments for the biotechnology company.